BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8363777)

  • 1. Cell-mediated immunity in HIV infection.
    Clerici M
    AIDS; 1993; 7 Suppl 1():S135-40. PubMed ID: 8363777
    [No Abstract]   [Full Text] [Related]  

  • 2. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV/AIDS vaccines: 2007.
    Robinson HL
    Clin Pharmacol Ther; 2007 Dec; 82(6):686-93. PubMed ID: 17971817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
    Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA
    Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576
    [No Abstract]   [Full Text] [Related]  

  • 5. A brief history of HIV vaccine research: stepping back to the drawing board?
    Miedema F
    AIDS; 2008 Sep; 22(14):1699-703. PubMed ID: 18753857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping the future of HIV vaccines.
    Nabel GJ
    Nat Rev Microbiol; 2007 Jul; 5(7):482-4. PubMed ID: 17571457
    [No Abstract]   [Full Text] [Related]  

  • 7. Cellular immune responses to HIV.
    McMichael AJ; Rowland-Jones SL
    Nature; 2001 Apr; 410(6831):980-7. PubMed ID: 11309628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development.
    Betts MR; Gray CM; Cox JH; Ferrari G
    Expert Rev Vaccines; 2006 Aug; 5(4):505-16. PubMed ID: 16989631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterologous prime-boost vaccination strategies for HIV-1: augmenting cellular immune responses.
    Newman MJ
    Curr Opin Investig Drugs; 2002 Mar; 3(3):374-8. PubMed ID: 12054082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection from HIV infection or AIDS?
    Miedema F; Meyaard L; Klein MR
    Science; 1993 Nov; 262(5136):1074-6. PubMed ID: 8235627
    [No Abstract]   [Full Text] [Related]  

  • 11. HIV type 1-specific helper T cells: a critical host defense.
    Rosenberg ES; Walker BD
    AIDS Res Hum Retroviruses; 1998 Jun; 14 Suppl 2():S143-7. PubMed ID: 9672231
    [No Abstract]   [Full Text] [Related]  

  • 12. Progress and obstacles in the development of an AIDS vaccine.
    Letvin NL
    Nat Rev Immunol; 2006 Dec; 6(12):930-9. PubMed ID: 17124514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects.
    Fernandez-Cruz E; Moreno S; Navarro J; Clotet B; Bouza E; Carbone J; Peña JM; Pérez Molina J; Podzamczer D; Rubio R; Ocaña I; Pulido F; Viciana P; Maradona JA; Blazquez R; Barros C; Quereda C; Rodriguez-Sainz C; Gil J; Abad ML; Díaz L; Cantó C; Muñoz MA; Ferrer E; Jou A; Sirera G; Díaz M; Lopez F; Gatell JM; Gonzalez-Lahoz J;
    Vaccine; 2004 Aug; 22(23-24):2966-73. PubMed ID: 15297045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New strategies to combat HIV: augmenting antiviral immunity.
    Smith KA; Boyle BA
    AIDS Read; 2003 Aug; 13(8):365-9, 382. PubMed ID: 14524321
    [No Abstract]   [Full Text] [Related]  

  • 15. Support for the RV144 HIV vaccine trial.
    Belshe R; Franchini G; Girard MP; Gotch F; Kaleebu P; Marthas ML; McChesney MB; McCullough R; Mhalu F; Salmon-Ceron D; Sekaly RP; van Rompay K; Verrier B; Wahren B; Weissenbacher M
    Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15247455
    [No Abstract]   [Full Text] [Related]  

  • 16. Human versus HIV: round 2 defeat in AIDS vaccine development.
    Lu S
    Expert Rev Vaccines; 2008 Mar; 7(2):151-3. PubMed ID: 18324884
    [No Abstract]   [Full Text] [Related]  

  • 17. Vaccines and immunology: elucidating immunity to HIV-1 and current prospects for AIDS vaccine development.
    Heeney JL; Hahn BH
    AIDS; 2000; 14 Suppl 3():S125-7. PubMed ID: 11086855
    [No Abstract]   [Full Text] [Related]  

  • 18. Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen.
    Moss RB; Wallace MR; Giermakowska WK; Webb E; Savary J; Chamberlin-Brandt C; Theofan G; Musil R; Richieri SP; Jensen FC; Carlo DJ
    J Infect Dis; 1999 Sep; 180(3):641-8. PubMed ID: 10438350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection.
    Lu W; Arraes LC; Ferreira WT; Andrieu JM
    Nat Med; 2004 Dec; 10(12):1359-65. PubMed ID: 15568033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can immune responses to human immunodeficiency virus be preserved, enhanced, or restored?
    Walker BD
    AIDS Clin Rev; 2000-2001; ():101-14. PubMed ID: 10999218
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.